Ibrahim Yakoub News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ibrahim yakoub. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ibrahim Yakoub Today - Breaking & Trending Today

RIC vs MAC Conditioning Regimens: No Difference in Outcomes of Allo-HCT for MDS

This study sought to determine if RIC conditioning regimen would lead to better outcomes for patients with MDS undergoing allo-HCT. ....

Ibrahim Yakoub , Ibrahim Yakoub Agha ,

Gilead Sciences (GILD) Granted EU Approval for Yescarta for Treatment of Relapsed or Refractory Follicular Lymphoma

Gilead Sciences (GILD) Granted EU Approval for Yescarta for Treatment of Relapsed or Refractory Follicular Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Christi Shaw , Ibrahim Yakoub , Nicola Mendelsohn , Lille University Hospital , American Society Of Hematology Meeting , European Commission , Gilead Company Nasdaq , Follicular Lymphoma Foundation , Gilead Company , Ibrahim Yakoub Agha , Hematopoietic Cell Transplantation , Cellular Therapy Unit , Lille University , Special Warnings , Adverse Reactions , Product Characteristics ,

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma


Credit: Dana-Farber Cancer Institute
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
In a study posted online today by the
New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer. These rates, and the duration of the responses, are significantly better than those produced by currently available therapies for patients with multiple relapses, according to investigators. ....

New York , United States , Nordrhein Westfalen , Region Flamande , Comunidad Autonoma De Cataluna , San Francisco , Dana Farber Cancer Institute , Baden Wuberg , United Kingdom , Institut Catala , Liping Huang , Triasi Pujol , Alessandro Rambaldi , Donna Reece , Nikhil Munshi , Jamien Connarn , Monica Massaro , David Siegel , Shari Kaiser , Nina Shah , Deepu Madduri , Michele Cavo , Hermann Einsele , Territoriale Papa Giovanni , Philippe Moreau , Yi Lin ,